What's on Your Mind?

Whether it's about your own experience or you're simply curious, we are interested to know how our work may be important to you.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
< News

Neuroptika Launches to Develop Novel Regenerative Treatment

June 22, 2023

CAMBRIDGE, MA, December 25, 2018 – Neuroptika today announced its initiation as a company to develop a novel therapeutic drug to protect and regenerate corneal nerves in ophthalmic diseases. Neuroptika is a spin out from Senju Pharmaceutical Co., Ltd, a privately held pharmaceutical company based in Osaka, Japan. Neuroptika will be headquartered in Cambridge Massachusetts and has raised ¥300M (USD $2.7M approx.) in seed funding.

NRO-1 is the lead compound for Neuroptika. In a nerve impairment model, NRO-1 accelerated nerve regeneration and led to the recovery of functional nerves and corneal sensitivity. NRO-1 is currently in a Phase 1 study with plans to advance to Phase 2 studies in patients with dry-eye disease and those needing post-LASIK care. NRO-1 is also being explored in glaucoma and Leber's hereditary optic neuropathy (LHON), since NRO-1 may also rescue degradation of nerves in retina.

“The opportunity to lead Neuroptika and the development of NRO-1 is incredibly exciting,” shared H. Timothy Min, Chief Executive Officer. “I look forward to building a world class team with the shared mission to improve patients’ lives by developing novel regenerative treatments.”

“While most dry-eye treatments focus on symptomatic therapy, NRO-1 is directed at the underlying cause of nerve degeneration in cornea,” stated Chiho Fukiage Ph.D., Chief Scientific Officer. “Establishing Neuroptika, with worldwide rights for NRO-1 enables this novel nerve-rescue therapy to treat patients with ophthalmic diseases.”